P578 Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainability

MLA

L Lontai, et al. “P578 Non-Medical Switch between Adalimumab Biosimilars and from the Originator Adalimumab to Biosimilars in Inflammatory Bowel Disease Patients – a Multicentre Study on Efficacy and Drug Sustainability.” Journal of Crohn’s and Colitis, vol. 16, Jan. 2022, pp. i518–19. EBSCOhost, https://doi.org/10.1093/ecco-jcc/jjab232.704.

APA

L Lontai, L Gonczi, F Balogh, N Komlodi, T Resal, K Farkas, T Molnar, P Golovics, E Schafer, T Szamosi, P Miheller, A Ilias, & P L Lakatos. (2022). P578 Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainability. Journal of Crohn’s and Colitis, 16, i518–i519. https://doi.org/10.1093/ecco-jcc/jjab232.704

Chicago

L Lontai, L Gonczi, F Balogh, N Komlodi, T Resal, K Farkas, T Molnar, et al. 2022. “P578 Non-Medical Switch between Adalimumab Biosimilars and from the Originator Adalimumab to Biosimilars in Inflammatory Bowel Disease Patients – a Multicentre Study on Efficacy and Drug Sustainability.” Journal of Crohn’s and Colitis 16 (January): i518–19. doi:10.1093/ecco-jcc/jjab232.704.